Regenerative Medicine & Immunotherapy

Research Summary

At VIC, we aim to develop innovative strategies that harness key components of the immune system to address some of the most pressing challenges in diabetes, neurotrauma, and neurodegenerative disease.

Our team is in active dialog with the Food and Drug Administration (FDA) regarding clinical testing of B cell immunotherapies. We have also initiated pilot preclinical studies with human stem cell-derived islets for type 1 diabetes treatment in non-human primates.

we employ the following strategies for tissue regeneration and immunotherapy: